Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the third quarter ended September 30, 2008.

"We continue to make rapid progress in both of our hepatitis C development programs," said Steve Worland Ph.D., President and CEO of Anadys. "We completed our first clinical study of ANA598 in healthy volunteers and have now completed the healthy volunteer portion of our ongoing ANA773 study. For both programs, we are very encouraged by the data and look forward to initiating patient dosing this quarter."

Financial Results

As of September 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $34.4 million.

During the third quarter of 2008 the Company had no revenue, compared to $21.5 million for the same quarter of 2007. The revenue in the third quarter of 2007 was primarily derived from the recognition of previously deferred revenue associated with an upfront payment and a milestone payment under a prior collaboration.

Research and development expenses were $7.6 million for the third quarter of 2008 and 2007. During the third quarter of 2008, cost savings derived from Anadys' completed strategic restructuring and associated termination of prior development programs were offset by a significant increase in ANA598 development costs.

General and administrative expenses were $2.1 million for the third quarter of 2008, compared to $2.4 million for the third quarter of 2007. The $0.3 million decrease primarily resulted from cost savi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, ... in critical areas, announced the closing of an underwritten public ... purchase up to an aggregate 3,500,000 shares of common stock, ... per warrant.  The warrants have a per share exercise price ...
(Date:12/24/2014)... December 23, 2014 “Preparative & ... HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, ... & Agriculture) - Forecasts to 2019” provides a ... opportunities, current market trends, and strategies impacting the ...
(Date:12/24/2014)... SoundConnect’s 2015 next generation ... communication technology, provide continued education and inform users ... demonstrates online communication features and benefits; empowering users ... innovative and powerful tools. , According to SoundConnect’s ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... 2 Matthew B. Wiener, PharmD, Chief,Executive Officer ... Leadership Award from the Colorado Cancer Coalition. The ... development of the Just-In-Time (JIT),enrollment methodology for cancer ... the evening of October 6th, at the St. ...
... Scheduled for Monday, October 6, 2008 at ... 2 ARCA biopharma, Inc., a,biopharmaceutical company ... cardiovascular diseases, today announced that,Richard Brewer, the ... Michael Bristow, M.D., ARCA,s chairman and chief ...
... Blood and Marrow Stem Cell,Transplantation Program at the ... is the first in the United States to ... from The,Joint Commission, the nation,s leading accrediting agency ... Transplantation Program also,recently became the first and only ...
Cached Biology Technology:Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition 2ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 2ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 3ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 4ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 5Stem Cell Transplantation Program at Hackensack University Medical Center: First in Nation to Receive Joint Commission Certification for Quality and First in New Jersey to be Named a Blue Distinction(R) Center for Specialty Care. 2Stem Cell Transplantation Program at Hackensack University Medical Center: First in Nation to Receive Joint Commission Certification for Quality and First in New Jersey to be Named a Blue Distinction(R) Center for Specialty Care. 3
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced ... 2015-2019" report to their offering. ... a technology used for the identification of individuals. Facial ... person such as nose, jaw edges, mouth, and the ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... (Feb. 19, 2007) X-rays have been used for ... at the U.S. Department of Energys (DOE) Argonne National ... technique that can take images of ultra-small structures buried ... cells such as cellular nuclei. Argonne scientists along ...
... challenges of distinguishing one nano-sized probe image from another ... researchers at Georgia Tech and Emory University made an ... a lot like a starry sky on a clear ... already made great strides in solving a problem very ...
... is at the center of some of the nation,s ... to global climate change. To provide a critical overview ... a summit of leading energy experts from the government, ... inform an Academies study under way called "America,s Energy ...
Cached Biology News:Lensless camera uses X-rays to view nanoscale materials and biological specimens 2Lensless camera uses X-rays to view nanoscale materials and biological specimens 3Astronomy technology brings nanoparticle probes into sharper focus 2Astronomy technology brings nanoparticle probes into sharper focus 3NAS to hold 2-day summit on energy issues 2
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Request Info...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: